Potential drug–drug interactions in the era of integrase strand transfer inhibitors: a cross-sectional single-center study in Japan
Abstract Background Potential drug–drug interactions (PDDIs) commonly occur because of aging and comorbidities in people living with human immunodeficiency virus (HIV; PLWH). Protease inhibitors and non-nucleoside reverse transcriptase inhibitors have been reported to cause PDDIs in these patients....
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2021-12-01
|
| Series: | Journal of Pharmaceutical Health Care and Sciences |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s40780-021-00226-7 |
| _version_ | 1818406486142877696 |
|---|---|
| author | Yusuke Kunimoto Ryosuke Matamura Hiroshi Ikeda Satoshi Fujii Tomoko Kimyo Manabu Kitagawa Hiromasa Nakata Masayoshi Kobune Atsushi Miyamoto Masahide Fukudo |
| author_facet | Yusuke Kunimoto Ryosuke Matamura Hiroshi Ikeda Satoshi Fujii Tomoko Kimyo Manabu Kitagawa Hiromasa Nakata Masayoshi Kobune Atsushi Miyamoto Masahide Fukudo |
| author_sort | Yusuke Kunimoto |
| collection | DOAJ |
| description | Abstract Background Potential drug–drug interactions (PDDIs) commonly occur because of aging and comorbidities in people living with human immunodeficiency virus (HIV; PLWH). Protease inhibitors and non-nucleoside reverse transcriptase inhibitors have been reported to cause PDDIs in these patients. However, there are few reports of PDDIs in the era of treatment using integrase strand transfer inhibitors. Therefore, we investigated PDDIs in Japanese PLWH receiving antiretroviral drugs (ARVs). Methods This was a cross-sectional observational study conducted in Japanese outpatients. All eligible patients who had received ARV therapy for at least 48 weeks were enrolled. The primary endpoint was the incidence of PDDIs detected using the Lexicomp® interface. Results Of the 71 eligible patients, 51 (71.8%) were prescribed concomitant non-ARV medications. In 21 patients (29.6%), PDDIs with the potential to reduce the effects of ARVs occurred, although the HIV load was suppressed in all cases. Polypharmacy (the use of ≥5 non-ARVs) was observed in 25 patients (35.2%). There was a significantly higher median number of non-ARV medications in the PDDI group than in the non-PDDI group (6 vs. 3, P < 0.001). Furthermore, the proportion of patients on polypharmacy was significantly higher in those with PDDIs than in those without PDDIs (81.0% vs. 26.7%, P < 0.001). Conclusions The incidence of PDDIs is relatively high in Japanese PLWH, even in the era of treatment using integrase strand transfer inhibitors. Therefore, it is important for patients and health care providers to be constantly aware of PDDIs associated with ARV treatment. |
| first_indexed | 2024-12-14T09:12:42Z |
| format | Article |
| id | doaj.art-36b085886ff641c9923eba261607d847 |
| institution | Directory Open Access Journal |
| issn | 2055-0294 |
| language | English |
| last_indexed | 2024-12-14T09:12:42Z |
| publishDate | 2021-12-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Pharmaceutical Health Care and Sciences |
| spelling | doaj.art-36b085886ff641c9923eba261607d8472022-12-21T23:08:31ZengBMCJournal of Pharmaceutical Health Care and Sciences2055-02942021-12-01711610.1186/s40780-021-00226-7Potential drug–drug interactions in the era of integrase strand transfer inhibitors: a cross-sectional single-center study in JapanYusuke Kunimoto0Ryosuke Matamura1Hiroshi Ikeda2Satoshi Fujii3Tomoko Kimyo4Manabu Kitagawa5Hiromasa Nakata6Masayoshi Kobune7Atsushi Miyamoto8Masahide Fukudo9Department of Pharmacy, Sapporo Medical University HospitalDepartment of Pharmacy, Sapporo Medical University HospitalDepartment of Hematology, Sapporo Medical University School of MedicineDepartment of Pharmacy, Sapporo Medical University HospitalDepartment of Pharmacy, Sapporo Medical University HospitalDepartment of Pharmacy, Sapporo Medical University HospitalDepartment of Pharmacy, Sapporo Medical University HospitalDepartment of Hematology, Sapporo Medical University School of MedicineDepartment of Pharmacy, Sapporo Medical University HospitalDepartment of Pharmacy, Sapporo Medical University HospitalAbstract Background Potential drug–drug interactions (PDDIs) commonly occur because of aging and comorbidities in people living with human immunodeficiency virus (HIV; PLWH). Protease inhibitors and non-nucleoside reverse transcriptase inhibitors have been reported to cause PDDIs in these patients. However, there are few reports of PDDIs in the era of treatment using integrase strand transfer inhibitors. Therefore, we investigated PDDIs in Japanese PLWH receiving antiretroviral drugs (ARVs). Methods This was a cross-sectional observational study conducted in Japanese outpatients. All eligible patients who had received ARV therapy for at least 48 weeks were enrolled. The primary endpoint was the incidence of PDDIs detected using the Lexicomp® interface. Results Of the 71 eligible patients, 51 (71.8%) were prescribed concomitant non-ARV medications. In 21 patients (29.6%), PDDIs with the potential to reduce the effects of ARVs occurred, although the HIV load was suppressed in all cases. Polypharmacy (the use of ≥5 non-ARVs) was observed in 25 patients (35.2%). There was a significantly higher median number of non-ARV medications in the PDDI group than in the non-PDDI group (6 vs. 3, P < 0.001). Furthermore, the proportion of patients on polypharmacy was significantly higher in those with PDDIs than in those without PDDIs (81.0% vs. 26.7%, P < 0.001). Conclusions The incidence of PDDIs is relatively high in Japanese PLWH, even in the era of treatment using integrase strand transfer inhibitors. Therefore, it is important for patients and health care providers to be constantly aware of PDDIs associated with ARV treatment.https://doi.org/10.1186/s40780-021-00226-7HIVPotential drug–drug interactionAntiretroviral therapyIntegrase strand transfer inhibitorsPolypharmacy |
| spellingShingle | Yusuke Kunimoto Ryosuke Matamura Hiroshi Ikeda Satoshi Fujii Tomoko Kimyo Manabu Kitagawa Hiromasa Nakata Masayoshi Kobune Atsushi Miyamoto Masahide Fukudo Potential drug–drug interactions in the era of integrase strand transfer inhibitors: a cross-sectional single-center study in Japan Journal of Pharmaceutical Health Care and Sciences HIV Potential drug–drug interaction Antiretroviral therapy Integrase strand transfer inhibitors Polypharmacy |
| title | Potential drug–drug interactions in the era of integrase strand transfer inhibitors: a cross-sectional single-center study in Japan |
| title_full | Potential drug–drug interactions in the era of integrase strand transfer inhibitors: a cross-sectional single-center study in Japan |
| title_fullStr | Potential drug–drug interactions in the era of integrase strand transfer inhibitors: a cross-sectional single-center study in Japan |
| title_full_unstemmed | Potential drug–drug interactions in the era of integrase strand transfer inhibitors: a cross-sectional single-center study in Japan |
| title_short | Potential drug–drug interactions in the era of integrase strand transfer inhibitors: a cross-sectional single-center study in Japan |
| title_sort | potential drug drug interactions in the era of integrase strand transfer inhibitors a cross sectional single center study in japan |
| topic | HIV Potential drug–drug interaction Antiretroviral therapy Integrase strand transfer inhibitors Polypharmacy |
| url | https://doi.org/10.1186/s40780-021-00226-7 |
| work_keys_str_mv | AT yusukekunimoto potentialdrugdruginteractionsintheeraofintegrasestrandtransferinhibitorsacrosssectionalsinglecenterstudyinjapan AT ryosukematamura potentialdrugdruginteractionsintheeraofintegrasestrandtransferinhibitorsacrosssectionalsinglecenterstudyinjapan AT hiroshiikeda potentialdrugdruginteractionsintheeraofintegrasestrandtransferinhibitorsacrosssectionalsinglecenterstudyinjapan AT satoshifujii potentialdrugdruginteractionsintheeraofintegrasestrandtransferinhibitorsacrosssectionalsinglecenterstudyinjapan AT tomokokimyo potentialdrugdruginteractionsintheeraofintegrasestrandtransferinhibitorsacrosssectionalsinglecenterstudyinjapan AT manabukitagawa potentialdrugdruginteractionsintheeraofintegrasestrandtransferinhibitorsacrosssectionalsinglecenterstudyinjapan AT hiromasanakata potentialdrugdruginteractionsintheeraofintegrasestrandtransferinhibitorsacrosssectionalsinglecenterstudyinjapan AT masayoshikobune potentialdrugdruginteractionsintheeraofintegrasestrandtransferinhibitorsacrosssectionalsinglecenterstudyinjapan AT atsushimiyamoto potentialdrugdruginteractionsintheeraofintegrasestrandtransferinhibitorsacrosssectionalsinglecenterstudyinjapan AT masahidefukudo potentialdrugdruginteractionsintheeraofintegrasestrandtransferinhibitorsacrosssectionalsinglecenterstudyinjapan |